Dysplastic nevi in association with multiple primary melanoma.

PubWeight™: 0.83‹?›

🔗 View Article (PMID 3338073)

Published in Cancer Res on February 15, 1988

Authors

L Titus-Ernstoff1, P H Duray, M S Ernstoff, R L Barnhill, P L Horn, J M Kirkwood

Author Affiliations

1: Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut 06510.

Articles by these authors

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol (2001) 4.84

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60

Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol (2000) 3.42

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1996) 3.30

Screening for cutaneous melanoma by skin self-examination. J Natl Cancer Inst (1996) 3.23

The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study. Ann Intern Med (1994) 3.20

Experimental Lyme arthritis in rats infected with Borrelia burgdorferi. J Infect Dis (1988) 3.02

Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68

Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol (1983) 2.65

Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol (2000) 2.37

Spirochetal antigens and lymphoid cell surface markers in Lyme synovitis. Comparison with rheumatoid synovium and tonsillar lymphoid tissue. Arthritis Rheum (1988) 2.21

Recent skin self-examination and doctor visits in relation to melanoma risk and tumour depth. Br J Dermatol (2012) 2.20

Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol (2001) 2.19

The histopathology of experimentally infected hamsters with the Lyme disease spirochete, Borrelia burgdorferi. Proc Soc Exp Biol Med (1986) 2.18

A factual, not arbitrary, basis for choice of resection margins in melanoma. Arch Dermatol (1996) 2.12

Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons. Lancet (1997) 2.09

Tissue-shrinkage correction factor in the calculation of prostate cancer volume. Am J Surg Pathol (1996) 2.06

Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol (2001) 2.06

Fatal pancarditis in a patient with coexistent Lyme disease and babesiosis. Demonstration of spirochetes in the myocardium. Ann Intern Med (1985) 2.04

Lyme arthritis. Spirochetes found in synovial microangiopathic lesions. Am J Pathol (1985) 2.03

Reliability of the histopathologic diagnosis of melanocytic dysplasia. The Dysplastic Nevus Panel. Arch Dermatol (1997) 2.02

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1998) 1.94

A quantitative model of invasive Pseudomonas infection in burn injury. J Burn Care Rehabil (1994) 1.91

Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res (1995) 1.85

Prevalence of Borrelia burgdorferi in white-footed mice and Ixodes dammini at Fort McCoy, Wis. J Clin Microbiol (1987) 1.82

Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res (1996) 1.78

Experimental infection of the hamster with Borrelia burgdorferi. Ann N Y Acad Sci (1988) 1.77

Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res (1991) 1.73

Spitz tumors in children: a grading system for risk stratification. Arch Dermatol (1999) 1.71

A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi. J Am Acad Dermatol (1994) 1.64

Nevomelanocytic proliferations in association with cutaneous malignant melanoma: a multivariate analysis. J Am Acad Dermatol (1989) 1.59

Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci U S A (1992) 1.58

Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility. Oncogene (2006) 1.53

A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 1.52

Correlation of histologic architectural and cytoplasmic features with nuclear atypia in atypical (dysplastic) nevomelanocytic nevi. Hum Pathol (1990) 1.51

High-dose cisplatin and dacarbazine in the treatment of metastatic melanoma. J Natl Cancer Inst (1990) 1.51

Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res (2000) 1.50

Typical, dysplastic, congenital, and Spitz nevi: a comparative immunohistochemical study. Hum Pathol (1989) 1.48

A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J Immunol Methods (1999) 1.46

Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. J Clin Oncol (2002) 1.43

Loss of heterozygosity on chromosome 13 is associated with advanced stage prostate cancer. J Urol (1999) 1.41

Leukemic vasculitis: a feature of leukemia cutis in some patients. Am J Clin Pathol (1997) 1.37

Human melanocytes cultured from nevi and melanomas. J Invest Dermatol (1986) 1.36

Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases. Cancer (1995) 1.33

Infantile myofibromatosis. Evidence for an autosomal-dominant disorder. Am J Surg Pathol (1984) 1.32

Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model. J Bone Joint Surg Am (1984) 1.30

SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas. Oncogene (2007) 1.29

Expression of sialyl-Lewis X, an E-selectin ligand, in inflammation, immune processes, and lymphoid tissues. Am J Pathol (1992) 1.29

Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int J Cancer (1993) 1.27

NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells. Cancer Res (2000) 1.26

Construction of a representative cDNA library from prostatic intraepithelial neoplasia. Cancer Res (1996) 1.23

In vivo description of dendritic cells in human renal cell carcinoma. J Urol (1999) 1.23

Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J Immunol Methods (1992) 1.22

Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys (1998) 1.22

Interferons in the treatment of human cancer. J Clin Oncol (1984) 1.22

Sunlamp use and the risk of cutaneous malignant melanoma: a population-based case-control study in Connecticut, USA. Int J Epidemiol (1998) 1.21

The outer surface protein A (OspA) vaccine against Lyme disease: efficacy in the rhesus monkey. Vaccine (1997) 1.21

Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci U S A (2000) 1.19

Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis (2000) 1.18

Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother Emphasis Tumor Immunol (1996) 1.16

Adenocarcinoid (mucinous carcinoid) of the appendix. Gastroenterology (1984) 1.15

Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol (2001) 1.14

Desmoplastic melanoma. Histopathology (1992) 1.14

Maternal-fetal transmission of the Lyme disease spirochete, Borrelia burgdorferi. Ann Intern Med (1985) 1.13

A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet (2003) 1.13

Langerhans cell histiocytosis of the female genital tract. Cancer (1991) 1.13

Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma. Cytotherapy (2006) 1.11

Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol (1998) 1.11

Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res (1997) 1.10

The surgical pathology of human Lyme disease. An enlarging picture. Am J Surg Pathol (1987) 1.10

Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res (1996) 1.10

Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist (2000) 1.09

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology (1997) 1.08

Clinical diagnosis of pigmented lesions using digital epiluminescence microscopy. Grading protocol and atlas. Arch Dermatol (1993) 1.08

Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol (1997) 1.08

Borrelial fasciitis: diffuse fasciitis and peripheral eosinophilia associated with Borrelia infection. Am J Dermatopathol (1996) 1.07

Atypical or worrisome features in cellular neurothekeoma: a study of 10 cases. Am J Surg Pathol (1998) 1.07

Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J Am Acad Dermatol (1982) 1.07

Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochem Biophys Res Commun (2000) 1.06

Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma. Cancer Res (1996) 1.06

Borrelia burgdorferi myositis: report of eight patients. J Neurol (1993) 1.05

Hepatobiliary lymphoepithelioma-like carcinoma associated with Epstein-Barr virus. Am J Clin Pathol (1998) 1.05

Patient knowledge, awareness, and delay in seeking medical attention for malignant melanoma. J Clin Epidemiol (1999) 1.04

Analysis of vascularity of human neurofibromas. J Am Acad Dermatol (1998) 1.03

Borrelia burgdorferi and Ixodes dammini prevalent in the greater Philadelphia area. J Infect Dis (1990) 1.03

High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med (1980) 1.02

gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells. Br J Cancer (2001) 1.02

Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Invest (2000) 1.02

Increased thickness of pregnancy-associated melanoma. Br J Dermatol (1995) 1.02

Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epithelium. J Urol (2001) 1.02

Unusual form of recurrent giant cell granuloma of the mandible and lower extremities in a patient with neurofibromatosis type 1. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1999) 1.02